Top Ten Trending Tech Products in Australia in 2017
It’s a booming scenario for technology in Australia as it’s growing more and more stronger in the continent with each…
Use and benefits of Cbd oil
CBD OILS: Cbd is a natural supplement, therefore it is perfect for who wants to relax and find pleasure without…
HS-UK Look Forward to an Exciting Optrafair 2019
Exhibiting on stand F50, HS-UK will be showcasing a large selection of its product portfolio, including; the gold-standard Haag-Streit BQ…
CORRECTION: CBD Market Could Outpace Entire Marijuana Market
Financialnewsmedia.com News Commentary ‘According to the (Brightfield”s) projections, there would be increases in just about every sector that sells CBD…
Zentiva Strengthens European Generic Footprint With Prague Manufacturing Site Investment
Zentiva is investing EUR 30 million to maximize its manufacturing site capabilities in Prague. The investment further strengthens Zentiva”s manufacturing…
MobileODT and Partners to Launch First Wide-Scale Deployment of AI screening for Cervical Cancer
MobileODT, developer of the Enhanced Visual Assessment (EVA) System, will partner with Genworks and Apollo Hospitals to deliver its FDA-cleared…
Exscientia Initiates Sixth AI Drug Discovery Partnership
Exscientia to receive up to CHF 67 million in upfront payments, research support, and milestone payments in discovery collaboration with…
Marler Clark: Managing Partner Bill Marler travels to South Africa to address Food Focus Listeria Conference
The Food Focus Conference comes during the largest Listeria outbreak in history which is centered in South Africa. To date,…
Tabuk Pharmaceuticals Signs a Commercial Agreement with Renapharma AB
Tabuk Pharmaceuticals Manufacturing Company (‘Tabuk’), one of the leading pharmaceutical companies in the Middle East and North Africa region, has entered…
Daiichi Sankyo Presents Phase 1 Data for EZH1/2 Dual Inhibitor DS-3201 in Patients with Non-Hodgkin Lymphomas at the 59th Annual Meeting of the American Society of Hematology
– In subgroup analyses, an overall response rate of 45.5 percent with DS-3201 was observed in patients with B-cell lymphomas…